Lynx1 Capital Management LP acquired a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 240,042 shares of the company's stock, valued at approximately $3,946,000. Upstream Bio comprises 1.5% of Lynx1 Capital Management LP's investment portfolio, making the stock its 11th biggest holding. Lynx1 Capital Management LP owned approximately 0.45% of Upstream Bio at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Moody Aldrich Partners LLC bought a new stake in shares of Upstream Bio in the 4th quarter worth approximately $1,229,000. Legal & General Group Plc bought a new position in shares of Upstream Bio during the fourth quarter worth about $28,000. Corebridge Financial Inc. acquired a new stake in shares of Upstream Bio in the 4th quarter worth about $142,000. Bain Capital Life Sciences Investors LLC acquired a new position in Upstream Bio during the 4th quarter valued at about $37,735,000. Finally, Geode Capital Management LLC bought a new position in Upstream Bio in the 4th quarter worth about $5,973,000.
Upstream Bio Stock Performance
Shares of UPB traded up $0.07 during mid-day trading on Friday, reaching $9.07. 183,183 shares of the company's stock traded hands, compared to its average volume of 322,149. Upstream Bio, Inc. has a 12 month low of $5.14 and a 12 month high of $29.46. The business's 50-day moving average price is $7.94 and its 200-day moving average price is $14.24.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
See Also
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
